Gilead, Arcus’ updated TIGIT data unlikely to resolve debates around space: #ASCO23

CHICAGO — Gilead and Arcus unveiled a fuller snapshot of a Phase II study testing their experimental cancer immunotherapy combo that showed lower progression-free survival rates than its previous update, results that are likely to spark further debate over the closely-watched clinical trial. Last December, the anti-TIGIT/anti-PD-L1 combo, positioned as…

Advertisement — Advertise with Biotech Networks